Mark E. Dmytruk sold $10k of DNA
See remarks at Ginkgo Bioworks Holdings, Inc.. 1,322 shares at an average of $7.58, traded Nov 4, 2024, filed Nov 6, 2024.
Score components
- +15RoleOfficer
- 0Trade size$10k at market
- 0Share of holdings soldSold 4.0% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +40.3%, 3m +96.9%, 6m -11.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001127602-24-026589, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 1, 2024 | MOption exercise Class A Common Stock | +1,634 | - | - | 31,871 | Nov 6, 2024 |
| Nov 1, 2024 | MOption exercise Class A Common Stock | +453 | - | - | 32,324 | Nov 6, 2024 |
| Nov 1, 2024 | MOption exercise Class A Common Stock | +572 | - | - | 32,896 | Nov 6, 2024 |
| Nov 1, 2024 | MOption exercise Class A Common Stock | +36 | - | - | 32,932 | Nov 6, 2024 |
| Nov 4, 2024 | SOpen-market sale Class A Common Stock | -1,322 | $7.58 | $10k | 31,610 | Nov 6, 2024 |
| Nov 1, 2024 | MOption exercise Restricted Stock Unitsderivative | -1,634 | - | - | 6,364 | Nov 6, 2024 |
| Nov 1, 2024 | MOption exercise Restricted Stock Unitsderivative | -453 | - | - | 12,688 | Nov 6, 2024 |
| Nov 1, 2024 | MOption exercise Restricted Stock Unitsderivative | -572 | - | - | 22,920 | Nov 6, 2024 |
| Nov 1, 2024 | MOption exercise Class B Common Stockderivative | -36 | - | - | 15,427 | Nov 6, 2024 |
Related signals
Other insiders at Ginkgo Bioworks Holdings, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 1Weak | Ginkgo Bioworks Holdings, Inc. | Steven P. Coen See remarks | $36k 2,403 shares | -5% | |
| 26Weak | DNAsell Ginkgo Bioworks Holdings, Inc. | Christian O Henry director | $35k 5,000 shares | -21% | |
| 37Weak | DNAsell Ginkgo Bioworks Holdings, Inc. | Christian O Henry director | $220k 20,000 shares | -45% | |
| 0Weak | DNAsell Ginkgo Bioworks Holdings, Inc. | Steven P. Coen See remarks | $3,843 310 shares | -3% | |
| 0Weak | DNAsell Ginkgo Bioworks Holdings, Inc. | Steven P. Coen See remarks | $11k 1,084 shares | -9% | |
| 8Weak | Ginkgo Bioworks Holdings, Inc. | Steven P. Coen See remarks | $2,624 346 shares | -4% | |
| 8Weak | Ginkgo Bioworks Holdings, Inc. | Mark E. Dmytruk See remarks | $5,355 706 shares | -2% | |
| 13Weak | Ginkgo Bioworks Holdings, Inc. | Steven P. Coen See remarks | $7,261 997 shares | -10% | |
| 8Weak | Ginkgo Bioworks Holdings, Inc. | Mark E. Dmytruk See remarks | $9,060 1,244 shares | -3% | |
| 8Weak | Ginkgo Bioworks Holdings, Inc. | Steven P. Coen See remarks | $3,051 395 shares | -5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.